Research

The Division of Nephrology is actively engaged in clinical, translational, and basic science research related to kidney diseases. 


CLINICAL RESEARCH
Clinical trials currently enrolling patients are listed below.  New trials are constantly being developed, so check back often and feel free to make an appointment for evaluation even if your disease is not represented currently.  Please click on the clinicaltrials.gov link for more information, or call us if interested in enrolling:  212-305-3273.

Principal Investigator Title Sponsor Status Columbia Protocol Identifier  ClinicalTrials.Gov Identifier
Gerald Appel, MD  A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability + Clinical Effect of Laquinimod in Active Lupus Nephritis Patients, in Combination with Standard of Care(MMF+Steroids) , LNLAQ201 TEVA Pharmaceuticals Enrolling IRB-AAAF0760  NCT01085097
           
Gerald Appel, MD  The Nephrotic Syndrome Study Network (NEPTUNE) NIDDK  Enrolling IRB-AAAI1558  NCT01240564
           
Gerald Appel, MD  Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients Centocor Pharmaceuticals Enrolling IRB-AAAI1090  NCT01470183
           
Pietro Canetta, MD  A Multicenter, Randomized, Prospective, Open-Label Trial of Rituximab in the Treatment of Progressive IgA Nephropathy, U3740s Mayo Clinic, Genentech Inc. and Biogen Idec Enrolling IRB-AAAE0092  NCT00498368
           
Pietro Canetta, MD  Novel Therapies for Resistant FSGS Phase II Clinical Trial Phased Innovation Award (FONT 2) NSLIJ / NIDDK  Enrolling IRB-AAAI1320  NCT00814255
           
Pietro Canetta, MD  A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar® Gel (Acthar) in Treatment-Resistant Subjects with Persistent Proteinuria and Nephrotic Syndrome due to Idiopathic Membranous Nephropathy (iMN), QSC01-MN-01 Questcor Pharmaceuticals Enrolling IRB-AAAI1745  NCT01386554 
           
David J. Cohen, MD  A 12 month, multicenter, randomized, open-label non-inferiority study comparing the safety and efficacy of concentrationcontrolled Everolimus with low dose tacrolimus to CellCept (MMF) with standard dose tacrolimus in de novo renal transplant recipients Novartis  Enrolling IRB-AAAF0776  NCT01025817
           
Jai Radhakrishnan, MD Multicenter, Open-label, Extension Study to Evaluate the Longterm Efficacy and Safety of Oral Tolvaptan Tablet Regimens in Subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD)  Otsuka Pharmaceutical Development & Commercialization, Inc. Enrollment by Invitation IRB-AAAI0073  NCT01214421


BASIC RESEARCH:
Please click on the faculty profiles for Drs. Al-Awqati, Landry, Oliver, Barasch, Gharavi, or Kiryluk to learn more about their research interests